Welcome to our dedicated page for Bristol-Myers Squibb Co SEC filings (Ticker: BMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bristol-Myers Squibb鈥檚 drug pipeline shifts with every FDA ruling and patent challenge, making its regulatory paperwork a critical read for anyone tracking biopharma risk and opportunity. Yet a single 10-K can exceed 250 pages of trial data, manufacturing details, and litigation notes.
Stock Titan brings these documents to life. Our platform delivers AI-powered summaries that turn dense R&D jargon into plain English, flags revenue swings drug by drug, and highlights patent-expiry timelines鈥攁ll in real time as each filing hits EDGAR. Whether you need the latest Bristol-Myers Squibb quarterly earnings report 10-Q filing or want to scan an Bristol-Myers Squibb 8-K material events explained, everything is one click away.
Use cases professionals rely on:
- Instant alerts for Bristol-Myers Squibb insider trading Form 4 transactions to gauge executive confidence.
- Side-by-side revenue trend charts pulled from every 10-Q so you can compare Opdivo and Eliquis growth without manual spreadsheet work.
- Concise red-flag notes inside the Bristol-Myers Squibb annual report 10-K simplified section鈥攑erfect for spotting looming patent cliffs.
- Full text search across the latest Bristol-Myers Squibb proxy statement executive compensation to understand incentive alignment.
Need real-time data? Our feed posts Bristol-Myers Squibb Form 4 insider transactions real-time within seconds of SEC acceptance. Curious about pipeline catalysts? Our AI tags every clinical update inside an 8-K so you never miss a material event. In short, this page is the fastest route to understanding Bristol-Myers Squibb SEC documents with AI and provides the deep Bristol-Myers Squibb earnings report filing analysis analysts demand.
Bristol-Myers Squibb (BMY) 鈥� Form 4 filing: EVP & Chief Medical Officer Cristian Massacesi reported the grant of 204,691 Restricted Stock Units (RSUs) on 08/01/2025. Each RSU converts into one share of BMY common stock upon vesting at no exercise cost.
Key terms:
- Vesting schedule: 25 % each year on the 1st鈥�4th anniversaries of the grant date (first tranche 08/01/2026; final tranche 08/01/2029).
- Ownership after grant: Massacesi now holds 204,691 derivative securities directly.
- Transaction code: 鈥淎鈥� (award) 鈥� no open-market purchase or sale occurred.
The award represents <0.01 % of BMY鈥檚 ~2.1 bn shares outstanding, so dilution is immaterial. The filing signals long-term incentive alignment but has no immediate earnings or cash-flow impact; therefore market effect should be minimal.
Bristol-Myers Squibb (BMY) filed an 8-K on 31-Jul-2025 to furnish, rather than file, its second-quarter 2025 earnings materials.
- Item 2.02: Exhibit 99.1 is the press release containing Q2-25 results.
- Item 7.01: Exhibit 99.2 is an investor presentation used for the 8:00 a.m. ET conference call.
- Both exhibits include non-GAAP figures with GAAP reconciliations; no financial metrics appear in the body of the 8-K itself.
- The furnished status limits Exchange Act 搂18 liability and prevents automatic incorporation into future filings unless specifically referenced.
- No other material transactions, governance changes or financing actions were disclosed.
The filing also lists NYSE-traded securities鈥攃ommon stock, 1.750 % notes due 2035, and Celgene CVRs鈥攁nd contains standard emerging-growth-company and Regulation FD boilerplate.
Form 8-K 鈥� Item 5.02 (Departure of Certain Officers)
On 25 July 2025, Bristol-Myers Squibb Company (NYSE: BMY) reported that Dr. Samit Hirawat, Executive Vice President, Chief Medical Officer & Head of Development, will step down from these roles effective 1 August 2025 and will fully exit the company on or before 1 November 2025. During the interim period he will act as an advisor.
Separation terms
- Cash severance governed by the U.S. Severance Benefits Plan.
- Pro-rated vesting of outstanding Market Share Units and Performance Share Units under the 2021 Stock Award & Incentive Plan.
- Prorated 2025 annual incentive under the Senior Executive Performance Incentive Plan.
No successor, strategic changes, or financial impact projections were disclosed. A related press release is furnished as Exhibit 99.1.
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
